AIM Vaccine Co. Ltd. announced that its wholly-owned subsidiary, AIM Rongyu (Ningbo) Biopharmaceutical Co., Ltd., has successfully passed the on-site inspection for registration of its self-developed serum-free iterative rabies vaccine, as organized by the Center for Drug Evaluation $(CDE)$ of the National Medical Products Administration (NMPA) of China. The vaccine has also completed Phase III clinical trials, demonstrating good safety, immunogenicity, and immune persistence, and has previously obtained the corresponding production license. This vaccine is currently the first of its kind to pass such regulatory milestones globally. No other beneficiary organizations were mentioned in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM Vaccine Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260205-12017035), on February 05, 2026, and is solely responsible for the information contained therein.